Advertisement

Fluorescence-Based Binding Assay for Screening Ligands of Angiotensin Receptors

  • Maiia E. Bragina
  • Nikolaos Stergiopulos
  • Rodrigo A. Fraga-Silva
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1614)

Abstract

Binding assay is a common technique used to characterize ability of a ligand to interact with a specific biological target. A number of parameters, such as binding affinity, receptor density, and association/dissociation rate constants, can be measured by means of this technique. In most cases, implementation of the binding assay requires specific infrastructure for labeling and detecting the ligand, which impedes realization of this technique in a standard laboratory. Here we describe a simple fluorescence-based binding assay for angiotensin peptides and receptors, which does not require complex equipment and can be used for initial screening of the novel ligands or mutational studies.

Key words

Binding assay Ligand Receptor Fluorescently labeled Screening Renin–angiotensin system 

References

  1. 1.
    Schiffrin EL (2002) Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 113(5):409–418CrossRefPubMedGoogle Scholar
  2. 2.
    Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160(6):1273–1292. doi: 10.1111/j.1476-5381.2010.00750.x CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bader M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50:439–465. doi: 10.1146/annurev.pharmtox.010909.105610 CrossRefPubMedGoogle Scholar
  4. 4.
    Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor mas. Proc Natl Acad Sci U S A 100(14):8258–8263. doi: 10.1073/pnas.1432869100 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Fraga-Silva RA, Ferreira AJ, Dos Santos RA (2013) Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor pathway in hypertension. Curr Hypertens Rep 15(1):31–38. doi: 10.1007/s11906-012-0324-1 CrossRefPubMedGoogle Scholar
  6. 6.
    Steckelings UM, Paulis L, Namsolleck P, Unger T (2012) AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 21(2):142–146. doi: 10.1097/MNH.0b013e328350261b CrossRefPubMedGoogle Scholar
  7. 7.
    Sridharan R, Zuber J, Connelly SM, Mathew E, Dumont ME (2014) Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim Biophys Acta 1838(1 Pt A):15–33. doi: 10.1016/j.bbamem.2013.09.005 CrossRefPubMedGoogle Scholar
  8. 8.
    de Jong LA, Uges DR, Franke JP, Bischoff R (2005) Receptor-ligand binding assays: technologies and applications. J Chromatogr B Anal Technol Biomed Life Sci 829(1–2):1–25. doi: 10.1016/j.jchromb.2005.10.002 CrossRefGoogle Scholar
  9. 9.
    Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112(8):1104–1111. doi: 10.1161/CIRCRESAHA.113.301077 CrossRefPubMedGoogle Scholar
  10. 10.
    Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW (2010) Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335(3):572–579. doi: 10.1124/jpet.110.173005 CrossRefPubMedGoogle Scholar
  11. 11.
    Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47(24):5995–6008. doi: 10.1021/jm049715t CrossRefPubMedGoogle Scholar
  12. 12.
    Slavik R, Herde AM, Bieri D, Weber M, Schibli R, Kramer SD, Ametamey SM, Mu L (2015) Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. Eur J Med Chem 92:554–564. doi: 10.1016/j.ejmech.2015.01.028 CrossRefPubMedGoogle Scholar
  13. 13.
    Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136(Pt 7):2217–2227. doi: 10.1093/brain/awt142 CrossRefPubMedGoogle Scholar
  14. 14.
    Auld DS, Farmen MW, Kahl SD, Kriauciunas A, McKnight KL, Montrose C, Weidner JR (2012) Receptor binding assays for HTS and drug discovery. In: Sittampalam GS, Coussens NP et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MDGoogle Scholar
  15. 15.
    Maguire JJ, Kuc RE, Davenport AP (2012) Radioligand binding assays and their analysis. In: Davenport AP (ed) Receptor binding techniques, vol 897, 3rd edn. Springer, New York, NYGoogle Scholar
  16. 16.
    Hulme EC, Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161(6):1219–1237. doi: 10.1111/j.1476-5381.2009.00604.x CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kim TK, Eberwine JH (2010) Mammalian cell transfection: the present and the future. Anal Bioanal Chem 397(8):3173–3178. doi: 10.1007/s00216-010-3821-6 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jankowski V, Tolle M, Santos RA, Gunthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J (2011) Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 25(9):2987–2995. doi: 10.1096/fj.11-185470 CrossRefPubMedGoogle Scholar
  19. 19.
    Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M, Santos RA (2004) Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor mas agonist in the mouse kidney. Hypertension 44(4):490–496. doi: 10.1161/01.HYP.0000141438.64887.42 CrossRefPubMedGoogle Scholar
  20. 20.
    Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, de Almeida AP, Rotman G, Santos RA (2010) Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 56(1):112–120. doi: 10.1161/HYPERTENSIONAHA.110.152942 CrossRefPubMedGoogle Scholar
  21. 21.
    Fraga-Silva RA, Pinheiro SV, Goncalves AC, Alenina N, Bader M, Santos RA (2008) The antithrombotic effect of angiotensin-(1–7) involves mas-mediated NO release from platelets. Mol Med 14(1–2):28–35. doi: 10.2119/2007-00073.Fraga-Silva PubMedPubMedCentralGoogle Scholar
  22. 22.
    Leal MC, Pinheiro SV, Ferreira AJ, Santos RA, Bordoni LS, Alenina N, Bader M, Franca LR (2009) The role of angiotensin-(1–7) receptor mas in spermatogenesis in mice and rats. J Anat 214(5):736–743. doi: 10.1111/j.1469-7580.2009.01058.x CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor MAS knockout mice. Hypertension 47(5):996–1002. doi: 10.1161/01.HYP.0000215289.51180.5c CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Maiia E. Bragina
    • 1
  • Nikolaos Stergiopulos
    • 1
  • Rodrigo A. Fraga-Silva
    • 1
  1. 1.Laboratory of Hemodynamics and Cardiovascular TechnologyInstitute of Bioengineering, Ecole Polytechnique Fédérale de LausanneLausanneSwitzerland

Personalised recommendations